文献速递临床试验与 GCP基础与转化研究

不同剂量花生表皮免疫治疗贴片对比安慰剂对花生敏感患者反应的影响:一项随机临床试验

Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项2b期双盲安慰剂对照剂量探索试验纳入221例6-55岁花生过敏患者,随机接受50μg、100μg、250μg花生蛋白贴片或安慰剂贴片治疗12个月。250μg组应答率50.0%显著高于安慰剂组25.0%(差异25.0%,95%CI 7.7%-42.3%,P=0.01),100μg组与安慰剂无显著差异;6-11岁亚组中250μg组应答率差异显著(34.2%,95%CI 11.1%-57.3%,P=0.008),青少年/成人亚组无显著差异。作者认为这些发现需开展3期试验。

要点

  • 12个月时250μg花生贴片应答率50.0%,安慰剂组25.0%,差异25.0%(95%CI 7.7%-42.3%,P=0.01)。
  • 6-11岁亚组中250μg组与安慰剂组应答率差异34.2%(95%CI 11.1%-57.3%,P=0.008)。
  • 未观察到剂量相关的严重不良事件,1年总体中位依从性97.6%。

核心结论

  • 在花生过敏患者剂量探索试验中,250μg花生贴片治疗12个月后较安慰剂贴片产生显著治疗应答。
  • 作者认为这些发现需开展3期试验。

研究设计与样本

  • 2b期双盲、安慰剂对照、剂量探索试验,纳入来自22个中心的6-55岁花生过敏患者221例。
  • 患者随机(1:1:1:1)接受含50μg(n=53)、100μg(n=56)、250μg(n=56)花生蛋白的表皮贴片或安慰剂贴片(n=56),每日贴敷12个月。
  • 研究时间为2012年7月31日至2014年7月31日,开放标签延长期于2016年9月29日完成。
  • 入组条件为花生敏感且双盲安慰剂对照食物激发试验阳性,诱发剂量≤300mg花生蛋白。

主要发现

  • 221例随机患者中位年龄11岁(四分位1、3:8、16),女性占37.6%,93.7%完成试验。
  • 第12个月250μg组应答28例(50.0%)vs 安慰剂组14例(25.0%),差异25.0%(95%CI 7.7%-42.3%,P=0.01)。
  • 安慰剂贴片与100μg贴片之间无显著差异;因统计检验层级规则,50μg贴片未与安慰剂比较。
  • 年龄组交互作用仅对250μg贴片显著(P=0.04);6-11岁亚组中250μg组应答15例(53.6%)vs 安慰剂组6例(19.4%),差异34.2%(95%CI 11.1%-57.3%,P=0.008);青少年/成人亚组中250μg组13例(46.4%)vs 安慰剂组8例(32.0%),差异14.4%(95%CI -11.6%至40.4%,P=0.40)。
  • 未观察到剂量相关的严重不良事件;第1年发生1次及以上治疗中出现的不良事件(TEAE,主要为局部皮肤反应)的患者比例在各组相似:50μg组100%、100μg组98.2%、250μg组100%、安慰剂组92.9%;1年总体中位依从性97.6%,因治疗相关不良事件退出率0.9%。

关键数值与推荐

  • 主要疗效终点为12个月后各组与安慰剂贴片相比的治疗应答者百分比(应答定义为诱发剂量较基线增加≥10倍和/或达到≥1000mg花生蛋白)。
  • 250μg组应答率50.0% vs 安慰剂组25.0%,差异25.0%(95%CI 7.7%-42.3%,P=0.01)。
  • 6-11岁亚组中250μg组应答率53.6% vs 安慰剂组19.4%,差异34.2%(95%CI 11.1%-57.3%,P=0.008)。
  • 青少年/成人亚组中250μg组应答率46.4% vs 安慰剂组32.0%,差异14.4%(95%CI -11.6%至40.4%,P=0.40),未达统计学显著。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 因统计检验层级规则,50μg贴片未与安慰剂比较。
  • 作者认为这些发现需开展3期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials. OBJECTIVE: To determine the optimal dose, adverse events (AEs), and efficacy of a peanut patch for peanut allergy treatment. DESIGN, SETTING, AND PARTICIPANTS: Phase 2b double-blind, placebo-controlled, dose-ranging trial of a peanut patch in peanut-allergic patients (6-55 years) from 22 centers, with a 2-year, open-label extension (July 31, 2012-July 31, 2014; extension completed September 29, 2016). Patients (n = 221) had peanut sensitivity and positive double-blind, placebo-controlled food challenges to an eliciting dose of 300 mg or less of peanut protein. INTERVENTIONS: Randomly assigned patients (1:1:1:1) received an epicutaneous peanut patch containing 50 μg (n = 53), 100 μg (n = 56), or 250 μg (n = 56) of peanut protein or a placebo patch (n = 56). Following daily patch application for 12 months, patients underwent a double-blind, placebo-controlled food challenge to establish changes in eliciting dose. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was percentage of treatment responders (eliciting dose: ≥10-times increase and/or reaching ≥1000 mg of peanut protein) in each group vs placebo patch after 12 months. Secondary end points included percentage of responders by age strata and treatment-emergent adverse events (TEAEs). RESULTS: Of 221 patients randomized (median age, 11 years [quartile 1, quartile 3: 8, 16]; 37.6% female), 93.7% completed the trial. A significant absolute difference in response rates was observed at month 12 between the 250-μg (n = 28; 50.0%) and placebo (n = 14; 25.0%) patches (difference, 25.0%; 95% CI, 7.7%-42.3%; P = .01). No significant difference was seen between the placebo patch vs the 100-μg patch. Because of statistical testing hierarchical rules, the 50-μg patch was not compared with placebo. Interaction by age group was only significant for the 250-μg patch (P = .04). In the 6- to 11-year stratum, the response rate difference between the 250-μg (n = 15; 53.6%) and placebo (n = 6; 19.4%) patches was 34.2% (95% CI, 11.1%-57.3%; P = .008); adolescents/adults showed no difference between the 250-μg (n = 13; 46.4%) and placebo (n = 8; 32.0%) patches: 14.4% (95% CI, -11.6% to 40.4%; P = .40). No dose-related serious AEs were observed. The percentage of patients with 1 or more TEAEs (largely local skin reactions) was similar across all groups in year 1: 50-μg patch = 100%, 100-μg patch = 98.2%, 250-μg patch = 100%, and placebo patch = 92.9%. The overall median adherence was 97.6% after 1 year; the dropout rate for treatment-related AEs was 0.9%. CONCLUSIONS AND RELEVANCE: In this dose-ranging trial of peanut-allergic patients, the 250-μg peanut patch resulted in significant treatment response vs placebo patch following 12 months of therapy. These findings warrant a phase 3 trial. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01675882.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sampson HA, Shreffler WG, Yang WH, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. 2017. PMID: 29136445. doi:10.1001/jama.2017.16591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。